According to a report in the newspaper, two volunteers had “severe neurological illness” after receiving test doses of the COVID-19 vaccine developed by AstraZeneca and Oxford University in the UK The New York Times.
The media indicate that there are two women. To date, it cannot be confirmed that these conditions were the result of receiving the test vaccine. A study has not been reported to confirm this, although the report said they both had the same disease.
Experts were particularly concerned about the AstraZeneca vaccine trials that started in the UK in April due to the company’s refusal to provide details of serious neurological conditions in the case of two participants; Both women who received their experimental vaccine in the UK, ”the newspaper stated.
“These cases resulted in the company stop testing twice, the second time earlier this month. Studies have restarted in the UK, Brazil, India and South Africa, but are still paused in the US. Until now, about 1
According to the article in the American media, AstraZeneca had not confirmed the diagnosis of the second patient with the disease during the tests, although a person familiar with the situation stated, on condition of anonymity, that the disease had been identified as transverse myelitis who had another who had another Volunteers.
Earlier this month it was first known that AstraZeneca “voluntarily” stopped testing the vaccine it was developing with Oxford University after it was discovered that one of the volunteers had developed an “unexplained” disease.
Then, on September 12, he said he had received approval from the UK authorities to restart the tests to make sure they were safe.
Last August, it was announced that Mexico and Argentina would be participating in the manufacture and distribution of the AstraZeneca and Oxford vaccine in the region, hailed as “good news for the people of Mexico” by President Andrés Manuel López Obrador over 73,000 People have died from coronavirus.